ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026
[Performance-related substance use in everyday life and work].
Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of potential performance-enhancing substances in everyday and working life is often linked to an increased workload, time pressure and limited opportunities for rest. This narrative review summarises recent studies on contexts of use, motives, substance groups, prevalence rates, and benefits and risks.The studies show that the use of performance-enhancing substances is primarily intended to support short-term performance demands. It occurs in particular in cases of fatigue, high cognitive demands, stress, emotional strain and physical complaints at work, including in connection with presenteeism. The substances used include stimulants, mood- or sleep-regulating agents, painkillers and dietary supplements. With the exception of the latter, these substances are often prescription-only; some stimulants are illegal. Prevalence figures vary widely due to differing study methods, settings and definitions of performance-enhancing substances. Generally accepted substances are used more frequently.The benefits of these substances are generally described as limited and context dependent. Key risks include the development of tolerance, dependence, residual effects and impairments affecting safety. Short-term benefits are often offset by long-term health and functional costs. In the context of public health and occupational medicine, performance-related substance use may indicate structural stressors. Prevention, care and work design should aim to ensure long-term functional capacity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.